John H. Rayson, M.D.
Chairman of the Board

John H. Rayson has been a director of MBI since 2004.  Dr. Rayson practiced family medicine for 27 years before joining MDS Metro Laboratory Services in 1994 as President and Chief Executive Officer, a position he held until 2001 when he became Chief Executive Officer and Executive Vice Chairman.  Dr. Rayson retired as CEO in June 2006 but continues as Executive Vice Chairman.  MDS Metro Laboratory Services is part of the diagnostics division of MDS Inc. (TSX: MDS; NYSE: MDZ).

Dr. Rayson holds an M.D. from the University of Manitoba.

Erinn B. Broshko, M.A., LL.B., M.B.A
Chief Executive Officer

Erinn B. Broshko has been MBI's Chief Executive Officer since May 2006. Prior to joining MBI, Mr. Broshko was a corporate and securities lawyer with the Vancouver law firm of Farris, Vaughan, Wills & Murphy LLP.  Mr. Broshko’s legal practice was focussed primarily on biotechnology companies and he represented clients in corporate transactions totalling in excess of $2.2 billion. 

Mr. Broshko holds a B.A. (hons) and M.A. from the University of Saskatchewan, an LL.B. from Dalhousie Law School and an M.B.A. from the University of British Columbia.

Bruce G. Cousins has been a director of MBI since May 2006. Mr. Cousins is the Chief Financial Officer of Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV). With Mr. Cousins as its CFO, Aspreva completed a $76 million private equity financing and a $113 million cross-border initial public offering on the Nasdaq National Market and Toronto Stock Exchange—the largest initial public offering for a biotechnology / biopharmaceutical company in Canadian history. During his tenure, Mr. Cousins has seen Aspreva evolve into an emerging global biopharmaceutical company.

Prior to joining Aspreva, Mr. Cousins spent 14 years with Johnson & Johnson (J&J) as the World Wide Financial Director for J&J's Wound Management Division in Somerville, New Jersey. As CFO of this US$500 million business unit, Mr. Cousins also held a key leadership role on the Global Management Board. Prior to entering the pharmaceutical industry, Mr. Cousins was a chartered accountant with Deloitte & Touche.

Mr. Cousins holds a B.Com. from McMaster University.

Dennis L. Grimaud

Dennis L. Grimaud has been a director of MBI since February 2008.  Mr. Grimaud has over 30 years of experience in the health care industry and over 18 years of experience in biotechnology and molecular diagnostics as an entrepreneur, senior executive and consultant.  Mr. Grimaud is currently the Chief Executive Officer of Theragnostix Reference Laboratories Inc., an innovative clinical laboratory providing diagnostic services for infectious disease.

From 2004 to 2006, Mr. Grimaud was the Chief Executive Officer of Genaco Biomedical Products, Inc., a molecular diagnostics company with proprietary multiplexing technology for infectious disease and cancer diagnostics.  In 2006, Mr. Grimaud led the sale of Genaco to global molecular diagnostics leader Qiagen (Nasdaq: QGEN). 

Wilbert J. Keon, O.C. M.D., F.R.C.S.

Wilbert J. Keon, O.C. M.D., F.R.C.S.(C), has been a director of MBI since 2004. Dr. Keon was a practicing academic surgeon from 1969 to September 2001. He founded the University of Ottawa Heart Institute in 1969, where he was the Chief Executive Officer until 2004.

Dr. Keon was a professor and the chair of the University of Ottawa Department of Surgery for 15 years and was the first Canadian surgeon to implant a total artificial heart as a bridge to transplant.

Dr. Keon has held appointments and elected offices in 36 national and international professional associates including past-president of the Medical Research Council of Canada. Dr. Keon has been honoured by his profession with numerous awards, is an Officer of the Order of Canada and a Senator of the Parliament of Canada.

Dr. Keon holds a B.Sc. and an M.D. from the University of Ottawa; an M.Sc. from McGill University; an F.R.C.S.(C) (General Surgery) from the University of Toronto and an F.R.C.S.(C) (Cardiac Surgery) from Harvard University.

R. Hector MacKay-Dunn, Q.C.

R. Hector MacKay-Dunn, Q.C. has been MBI’s Corporate Secretary since 2005 and a director since August 2007. He is a senior partner at the Vancouver law firm Farris, Vaughan, Wills & Murphy LLP. Mr. MacKay-Dunn has over 25 years of experience advising senior public and early-stage private companies on corporate and general matters, complex domestic and cross-border public and private securities offerings, mergers and acquisitions and international partnering transactions.

Mr. MacKay-Dunn is recognized by LEXPERT American Lawyer Media (2005) as one of Canada’s Top 100 Corporate Lawyers in Canada-US Cross Border Transactions and is the sole British Columbia Leading Lawyer named in the field of Technology and Biotechnology. He is chair of the BC Innovation Council, a Provincial Crown Agency; a director of Genome British Columbia; and a member of the UBC Faculty of Science Dean’s Advisory Council and the Simon Fraser University Biotech Advisory Council. He was appointed Queen’s Counsel by the British Columbia Cabinet in 2003.

Mr. Mackay-Dunn holds a B.A. and LL.B. from the University of British Columbia.

Bruce H. Sells, Ph.D.

Bruce H. Sells, Ph.D. has been a director of MBI since 2004. In 1962 Dr. Sells held his first research position at St. Jude Children’s Research Hospital in Memphis, Tennessee. Dr. Sells, initiated an exploration into the biogenesis of ribosome particles and published 110 papers about the topic throughout his career.

In 1972 Dr. Sells moved to Memorial University of Newfoundland and as a professor and a director of Molecular Biology, he began Molecular Biology studies at the recently created medical school. Dr. Sells was Associate Dean of Basic Medical Sciences from 1979 to 1983. In 1982 he was appointed President of the Canadian Bio-chemistry Society and was elected Fellow of the Royal Society of Canada.

Dr. Sells has served on various national committees, including the Medical Research Council, the National Cancer Institute, the Royal Society of Canada, the Arthritis Society, National Research Council Subcommittee on Biological Phenomena and on the Selection Panel for the Steacie Award.

In 1983, Dr. Sells accepted the position of Dean of Biological Science at the University of Guelph, which he kept until his retirement in 1995. Dr. Sells is now Executive Director for the Canadian Federation of Biological Societies.

Dr. Sells holds a B.Sc. (Hons) from Carelton University, an M.A. from Queen’s University and a Ph.D. from McGill University.

Thillainathan Yoganathan, Ph.D.

Thillainathan Yoganathan, Ph.D. is MBI's founder and an expert in gene expression technology and signalling pathways.

Dr. Yoganathan has over 18 years of experience in scientific research, with 15 years spent in biotechnology.  Dr. Yoganathan is the author of numerous peer­-reviewed scientific papers and is the co-inventor of one patent and seven pending patent applications, one of which relates to MBI's Hematalogical Cancer Profiling System. He is elected as a member of the American Association For Cancer Research and is also a member of the American Association for the Advancement of Science and the Canadian Academy for the Advancement of Science.  Dr. Yoganathan is also a mentor for the student biotechnology network (SBN) of British Columbia.  Dr. Yoganathan holds a B.Sc. (Honours) from the University of North London, an M.Sc. from the University of Sussex and a Ph.D. from the University of Oslo.